Total Payments
$15,580
2024 Payments
$3,665
Companies
25
Transactions
68
Medicare Patients
1,625
Medicare Billing
$168,078
Payment Breakdown by Category
Other$8,370 (53.7%)
Consulting$3,425 (22.0%)
Food & Beverage$3,168 (20.3%)
Travel$475.02 (3.0%)
Education$141.68 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $8,370 | 5 | 53.7% |
| Consulting Fee | $3,425 | 1 | 22.0% |
| Food and Beverage | $3,168 | 57 | 20.3% |
| Travel and Lodging | $475.02 | 2 | 3.0% |
| Education | $141.68 | 3 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CSL Behring | $5,095 | 9 | $0 (2020) |
| Akcea Therapeutics, Inc. | $4,605 | 5 | $0 (2020) |
| Biogen, Inc. | $3,754 | 10 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $267.40 | 5 | $0 (2019) |
| Amgen Inc. | $214.70 | 2 | $0 (2018) |
| ABBVIE INC. | $186.20 | 3 | $0 (2024) |
| Medtronic USA, Inc. | $163.35 | 1 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $141.99 | 4 | $0 (2023) |
| Allergan, Inc. | $137.13 | 3 | $0 (2020) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $128.37 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,665 | 6 | Biogen, Inc. ($3,474) |
| 2023 | $203.64 | 5 | Teva Pharmaceuticals USA, Inc. ($96.49) |
| 2022 | $112.53 | 1 | Horizon Therapeutics plc ($112.53) |
| 2021 | $95.30 | 1 | AbbVie Inc. ($95.30) |
| 2020 | $5,365 | 10 | Akcea Therapeutics, Inc. ($4,605) |
| 2019 | $967.25 | 24 | Biogen, Inc. ($262.67) |
| 2018 | $754.02 | 10 | Alexion Pharmaceuticals, Inc. ($232.00) |
| 2017 | $4,417 | 11 | CSL Behring ($4,324) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 10/07/2024 | Biogen, Inc. | SPINRAZA (Biological), SKYCLARYS | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Neurology | ||||||
| 10/03/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $102.59 | General |
| Category: Neurology | ||||||
| 07/19/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Neurology | ||||||
| 03/07/2024 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: Neurology | ||||||
| 02/02/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $72.19 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2023 | MITSUBISHI TANABE PHARMA AMERICA, INC. | Radicava (Drug) | Education | In-kind items and services | $28.47 | General |
| Category: Amyotrophic Lateral Sclerosis | ||||||
| 07/21/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.13 | General |
| 07/17/2023 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Neurology | ||||||
| 04/26/2023 | Teva Pharmaceuticals USA, Inc. | — | Education | In-kind items and services | $96.49 | General |
| 02/04/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $29.08 | General |
| 07/22/2022 | Horizon Therapeutics plc | UPLIZNA (Drug) | Food and Beverage | In-kind items and services | $112.53 | General |
| Category: UPLIZNA | ||||||
| 10/28/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $95.30 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Honoraria | Cash or cash equivalent | $730.00 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Honoraria | Cash or cash equivalent | $1,830.00 | General |
| Category: NEUROLOGY | ||||||
| 11/11/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $93.40 | General |
| Category: NEUROLOGY | ||||||
| 08/31/2020 | CSL Behring | Hizentra (Biological) | Honoraria | Cash or cash equivalent | $600.00 | General |
| Category: Immunology | ||||||
| 02/28/2020 | Sarepta Therapeutics, Inc. | Exondys 51 (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Genetic Disease | ||||||
| 02/03/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | Cash or cash equivalent | $106.22 | General |
| Category: NEUROSCIENCE | ||||||
| 01/31/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Honoraria | In-kind items and services | $1,830.00 | General |
| Category: NEUROLOGY | ||||||
| 01/31/2020 | Akcea Therapeutics, Inc. | TEGSEDI (Drug) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: NEUROLOGY | ||||||
| 01/31/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $25.98 | General |
| 01/29/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: NEUROSCIENCE | ||||||
| 08/14/2019 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $124.93 | General |
| Category: Immunology | ||||||
| 08/08/2019 | Biogen, Inc. | SPINRAZA (Biological) | Food and Beverage | Cash or cash equivalent | $102.22 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 419 | 458 | $171,097 | $44,781 |
| 2022 | 13 | 419 | 457 | $165,809 | $43,439 |
| 2021 | 15 | 387 | 439 | $151,049 | $40,731 |
| 2020 | 13 | 400 | 431 | $154,670 | $39,127 |
Total Patients
1,625
Total Services
1,785
Medicare Billing
$168,078
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 83 | 97 | $31,913 | $8,902 | 27.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 64 | 72 | $20,448 | $5,742 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 35 | $15,505 | $5,000 | 32.2% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 30 | 30 | $18,450 | $3,955 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $12,580 | $3,342 | 26.6% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 28 | 28 | $13,076 | $3,024 | 23.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 38 | 41 | $9,143 | $2,610 | 28.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $10,521 | $2,588 | 24.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 41 | 47 | $8,648 | $2,444 | 28.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 15 | 15 | $11,010 | $2,276 | 20.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $9,162 | $2,056 | 22.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 23 | 23 | $7,567 | $1,964 | 26.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 14 | $3,074 | $878.02 | 28.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 78 | $25,662 | $6,979 | 27.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 77 | 82 | $23,288 | $6,909 | 29.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 43 | 43 | $26,445 | $5,843 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $13,838 | $3,337 | 24.1% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 46 | 56 | $10,304 | $3,072 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 22 | $9,746 | $3,040 | 31.2% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 18 | 18 | $13,212 | $2,916 | 22.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $10,857 | $2,795 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 41 | $9,143 | $2,789 | 30.5% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 23 | 24 | $11,208 | $2,586 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $6,513 | $1,746 | 26.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 14 | $3,074 | $776.92 | 25.3% |
About Dr. Sara Austin, M.D
Dr. Sara Austin, M.D is a Neurology healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770695397.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sara Austin, M.D has received a total of $15,580 in payments from pharmaceutical and medical device companies, with $3,665 received in 2024. These payments were reported across 68 transactions from 25 companies. The most common payment nature is "Honoraria" ($8,370).
As a Medicare-enrolled provider, Austin has provided services to 1,625 Medicare beneficiaries, totaling 1,785 services with total Medicare billing of $168,078. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Austin, TX
- Active Since 08/31/2006
- Last Updated 01/02/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770695397
Products in Payments
- Hizentra (Biological) $5,095
- TEGSEDI (Drug) $4,605
- SKYCLARYS (Drug) $3,425
- SOLIRIS (Drug) $267.40
- Aimovig (Biological) $214.70
- UBRELVY (Drug) $214.13
- SPINRAZA (Biological) $168.50
- TYSABRI (Biological) $155.48
- Radicava (Drug) $128.37
- INBRIJA (Drug) $122.74
- UPLIZNA (Drug) $112.53
- GAMMAGARD (Biological) $109.33
- VYVGART HYTRULO (Drug) $102.59
- QULIPTA (Drug) $72.19
- AJOVY (Drug) $45.50
- LUMIZYME (Drug) $22.21
- Duopa (Drug) $18.71
- BOTOX (Biological) $18.30
- Gamunex-C (Biological) $17.65
- NORTHERA (Drug) $16.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Austin
Dr. Elliot Frohman, Md Phd, MD PHD
Neurology — Payments: $633,909
Neurology $633,909
Dr. David Morledge, M.d, M.D
Neurology — Payments: $180,453
Neurology $180,453
Dr. Sami Aboumatar, M.d, M.D
Neurology — Payments: $159,184
Neurology $159,184
Dr. Subhashie Wijemanne, M.d, M.D
Neurology — Payments: $140,816
Neurology $140,816
Dr. Krishna Pokala, Md, MD
Neurology — Payments: $103,512
Neurology $103,512
Dr. Rajat Gupta, M.d, M.D
Neurology — Payments: $91,931
Neurology $91,931